Article

Dorzolomide HCI OK for use in children

The FDA has approved Merck Human Health's dorzolomide HCI (Trusopt) ophthalmic solution 2% for use in pediatric patients. The drug is used to treat elevated IOP in patients with ocular hypertension or open-angle glaucoma.

Related Videos
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
Edward Manche, MD
Related Content
Vyluma announces NMPA of China accepts drug application of NVK002 (low-dose atropine 0.01%) for myopia progression in children
January 30th 2025

Vyluma announces NMPA of China accepts drug application of NVK002 (low-dose atropine 0.01%) for myopia progression in children

ROP: Treating and preventing blindness in preterm babies
October 18th 2021

ROP: Treating and preventing blindness in preterm babies

Microdrops show promise for safer retinopathy of prematurity screening in preterm infants
January 3rd 2025

Microdrops show promise for safer retinopathy of prematurity screening in preterm infants

Managing a changing landscape of IRD pediatric cases
May 10th 2021

Managing a changing landscape of IRD pediatric cases

Strabismus in animation: study highlights harmful stereotypes in children's films
November 28th 2024

Strabismus in animation: study highlights harmful stereotypes in children's films

Early vision screening is key to slowing myopia progression in children
November 28th 2024

Early vision screening is key to slowing myopia progression in children

© 2025 MJH Life Sciences

All rights reserved.